| Target Price | €17.34 |
| Price | €16.66 |
| Potential |
4.08%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Kempower 2026 .
The average Kempower target price is €17.34.
This is
4.08%
register free of charge
€21.00
26.05%
register free of charge
€13.13
21.19%
register free of charge
|
|
| A rating was issued by 13 analysts: 3 Analysts recommend Kempower to buy, 2 to hold and 8 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kempower stock has an average upside potential 2026 of
4.08%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 223.70 | 265.88 |
| 21.12% | 18.86% | |
| EBITDA Margin | -8.28% | 3.07% |
| 149.88% | 137.08% | |
| Net Margin | -10.38% | -1.63% |
| 187.30% | 84.30% |
6 Analysts have issued a sales forecast Kempower 2025 . The average Kempower sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Kempower EBITDA forecast 2025. The average Kempower EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Kempower Analysts have issued a net profit forecast 2025. The average Kempower net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | -0.42 | -0.08 |
| 168.85% | 80.95% | |
| P/E | negative | |
| EV/Sales | 3.33 |
6 Analysts have issued a Kempower forecast for earnings per share. The average Kempower EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


